Welcome to our dedicated page for Iridex news (Ticker: IRIX), a resource for investors and traders seeking the latest updates and insights on Iridex stock.
Iridex Corporation develops, manufactures, and markets laser-based medical systems, delivery devices, procedure probes, accessories, and consumable instrumentation for ophthalmology. Its products support treatment of glaucoma, diabetic macular edema, and other retinal diseases, with proprietary MicroPulse® technology used across parts of its portfolio.
Iridex news commonly covers quarterly and annual financial results, business updates, product-family activity for systems such as Cyclo G6®, retina laser platforms including PASCAL®, IQ 532®, IQ 577®, and OcuLight® TX, and clinical literature involving MicroPulse transscleral laser therapy. Company updates also address commercial partnerships, U.S. direct sales, international distributor activity, operational efficiency measures, and Nasdaq listing-status matters.
Summary not available.
Iridex Corporation (Nasdaq: IRIX) reported a 6% increase in full-year revenue to $57 million for 2022, driven by strong sales of its Cyclo G6 glaucoma products. In Q4 2022, total revenue was $15.2 million, with a record 16,400 Cyclo G6 probes sold, up 9% year-over-year. However, retina product revenue declined by 11% to $8.1 million. The company received FDA clearance for new laser systems in late 2022 and early 2023. Despite a net loss of $7.5 million for 2022, with a projected revenue of $57 million to $59 million for 2023, Iridex anticipates growth in Cyclo G6 probe sales between 9% and 12%. Cash reserves stand at $13.9 million.
Iridex Corporation (Nasdaq: IRIX), a leader in ophthalmic laser-based medical products, announced its participation in the 35th Annual Roth Conference in Laguna Niguel, CA. Management will present on March 14, 2023, at 11:00 am PT. Interested individuals can view a live and archived webcast of the presentation on the company's website.
Iridex focuses on innovative treatments for glaucoma and retinal diseases, utilizing its proprietary MicroPulse® technology. The company's products are distributed in over 100 countries, emphasizing their global reach and commitment to addressing serious eye conditions.
Iridex Corporation (NASDAQ: IRIX) announced the publication of Part 2 of the evidence-based guidelines for MicroPulse Transscleral Laser Therapy (TLT) at the 2023 American Glaucoma Society meeting in Austin, Texas. This guide, created by a panel of ten glaucoma experts, covers critical aspects such as anesthesia, surgical technique, and expected outcomes. It builds on Part 1, focusing on dosimetry and patient selection. Attendees can also view Dr. Syril Dorairaj's e-poster on MicroPulse TLT outcomes and demo the Sweep Management Software designed to optimize surgical techniques. Iridex continues to lead in ophthalmic laser-based treatments.
Iridex Corporation (NASDAQ: IRIX) will release its financial results for Q4 and full year 2022 after the market closes on March 9, 2023. The management team will host a conference call at 2:00 PM PT / 5:00 PM ET to discuss the results. Investors can access the live and recorded webcast on the Company’s website. Iridex specializes in innovative ophthalmic laser-based products for treating glaucoma and retinal diseases, utilizing its proprietary MicroPulse® technology. Their products are marketed in the U.S. and over 100 countries worldwide.
Iridex Corporation (Nasdaq: IRIX) announced preliminary financial results for the fourth quarter and full year ended December 31, 2022. Fourth quarter revenue is projected at $15.1 million to $15.3 million, unchanged year-over-year. The company achieved a record sale of 16,400 Cyclo G6 probes, an 8% increase from the previous year. Full year revenue is expected to be between $56.9 million and $57.1 million, reflecting a 6% growth. Cash and equivalents were approximately $13.9 million, with operating cash usage of $1.2 million in Q4.
Iridex Corporation (NASDAQ: IRIX), a leader in ophthalmic laser-based medical products, announced its participation in a fireside chat with Stifel's equity research analyst. This discussion is scheduled for December 8, 2022, at 9:00 a.m. PT / 12:00 p.m. ET. The event will be accessible via a live and archived webcast on the Company’s website. Iridex specializes in innovative laser systems for treating glaucoma and retinal diseases, using its proprietary MicroPulse® technology. The Company's products are distributed both in the U.S. and over 100 countries worldwide.
Iridex Corporation (Nasdaq: IRIX) reported a strong third quarter for 2022, achieving record revenue of $14.6 million, a 10% increase from the previous year. The company's gross margin rose to 44.1%, and the Cyclo G6 product family generated $3.5 million in revenue, boosted by 13,680 probes sold. Retina product revenue also increased to $8.8 million, a 13% rise year-over-year. However, the net loss decreased to $1.8 million, or $0.11 per share. The company expects total revenue for 2022 to reach $56 million to $58 million, representing 4% to 8% growth.
Iridex Corporation (NASDAQ: IRIX) will release its third-quarter 2022 financial results on November 10, 2022, after market close. A conference call with management will follow at 2:00 p.m. PT / 5:00 p.m. ET. Investors can access the live and recorded webcast on the Company’s website.
Iridex specializes in innovative ophthalmic laser-based medical products, primarily treating glaucoma and retinal diseases. Their products are distributed in the U.S., Germany, and over 100 other countries.
Iridex Corporation (NASDAQ: IRIX) is showcasing its innovative glaucoma treatment technologies at the 2022 American Academy of Ophthalmology annual meeting. The company introduces the Sweep Management Software for its Cyclo G6 Glaucoma Laser System, enhancing the precision of MicroPulse Transscleral Laser Therapy (TLT). This non-incisional treatment can reduce intraocular pressure by 25% to 45%. Iridex emphasizes its commitment to advancing glaucoma care through educational presentations and demonstrations at booth #5139.